399 related articles for article (PubMed ID: 29050459)
1. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
[TBL] [Abstract][Full Text] [Related]
2. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
3. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
[TBL] [Abstract][Full Text] [Related]
4. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
[TBL] [Abstract][Full Text] [Related]
5. Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.
Schneidawind D; Baker J; Pierini A; Buechele C; Luong RH; Meyer EH; Negrin RS
Blood; 2015 May; 125(22):3491-500. PubMed ID: 25795920
[TBL] [Abstract][Full Text] [Related]
6. Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells.
Steiner D; Brunicki N; Blazar BR; Bachar-Lustig E; Reisner Y
Exp Hematol; 2006 Jan; 34(1):66-71. PubMed ID: 16413392
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of graft-versus-host disease by double-negative regulatory T cells.
Young KJ; DuTemple B; Phillips MJ; Zhang L
J Immunol; 2003 Jul; 171(1):134-41. PubMed ID: 12816991
[TBL] [Abstract][Full Text] [Related]
8. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD.
Ermann J; Hoffmann P; Edinger M; Dutt S; Blankenberg FG; Higgins JP; Negrin RS; Fathman CG; Strober S
Blood; 2005 Mar; 105(5):2220-6. PubMed ID: 15546950
[TBL] [Abstract][Full Text] [Related]
9. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
10. IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.
Colonna L; Florek M; Leveson-Gower DB; Sega EI; Baker J; Smith AT; Negrin RS
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1557-65. PubMed ID: 23921175
[TBL] [Abstract][Full Text] [Related]
11. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.
Parmar S; Liu X; Tung SS; Robinson SN; Rodriguez G; Cooper LJ; Yang H; Shah N; Yang H; Konopleva M; Molldrem JJ; Garcia-Manero G; Najjar A; Yvon E; McNiece I; Rezvani K; Savoldo B; Bollard CM; Shpall EJ
Cytotherapy; 2014 Jan; 16(1):90-100. PubMed ID: 24480547
[TBL] [Abstract][Full Text] [Related]
12. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
[TBL] [Abstract][Full Text] [Related]
13. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
Pillai AB; George TI; Dutt S; Strober S
Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
[TBL] [Abstract][Full Text] [Related]
15. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
[TBL] [Abstract][Full Text] [Related]
16. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of Graft-Versus-Host Disease Control Efficacy by Adoptive Transfer of Type 1 Regulatory T Cells in Bone Marrow Transplant Model.
Jeon YW; Lim JY; Im KI; Kim N; Nam YS; Song YJ; Cho SG
Stem Cells Dev; 2019 Jan; 28(2):129-140. PubMed ID: 30381994
[TBL] [Abstract][Full Text] [Related]
18. Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo.
Ramos TL; Bolivar-Wagers S; Jin S; Thangavelu G; Simonetta F; Lin PY; Hirai T; Saha A; Koehn B; Su LL; Picton LK; Baker J; Lohmeyer JK; Riddle M; Eide C; Tolar J; Panoskaltsis-Mortari A; Wagner JE; Garcia KC; Negrin RS; Blazar BR
Blood; 2023 Mar; 141(11):1337-1352. PubMed ID: 36564052
[TBL] [Abstract][Full Text] [Related]
19. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Yao Y; Wang L; Zhou J; Zhang X
J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.
Theil A; Tuve S; Oelschlägel U; Maiwald A; Döhler D; Oßmann D; Zenkel A; Wilhelm C; Middeke JM; Shayegi N; Trautmann-Grill K; von Bonin M; Platzbecker U; Ehninger G; Bonifacio E; Bornhäuser M
Cytotherapy; 2015 Apr; 17(4):473-86. PubMed ID: 25573333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
